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The XVI International AIDS Conference, "AIDS
2006," took place August 13-18 and attracted
26,000 researchers, physicians, front-line workers, advocates and others involved in the fight
against HIV/AIDS from more than 170 countries. More than ever before,1 issues related to
HIV/AIDS in prisons were presented and discussed. On the first day of the conference, a
satellite meeting organized by the United
Nations (UN) Office on Drugs and Crime, the
Public Health Agency of Canada and the
Correctional Service of Canada debated issues
related to HIV/AIDS in prisons in great depth. At
the Conference itself, two oral sessions and a
large number of poster presentations were dedicated to HIV/AIDS in prisons. In addition, the
UN released an important guidance document
on issues related to HIV/AIDS in prisons. Most
activities focused on HIV prevention, although
delegates also heard about efforts to make HIV
treatment, including antiretrovirals, available to
prisoners in developing countries.
While it is impossible to provide a detailed
overview of all the prison-related developments
presented at AIDS 2006, this article will highlight
some of the relevant findings presented at the
conference.
Prevention: Moving from Evidence to Action
Probably the most important development at the
conference is an emerging consensus that there
is sufficient evidence of the effectiveness of HIV
prevention interventions in prisons, and that it is
time to move from evidence to action and implement these interventions in prisons. This
includes interventions such as condom provision that are currently the subject of much
debate in the United States, as well as interventions that have been successfully introduced in
other countries, but are rarely if ever discussed
in the United States, such as needle and syringe
programs in prisons.
Because of the importance of HIV prevention in
prisons to the overall fight against HIV/AIDS, the
World Health Organization (WHO) in 2005 com-

missioned a review of the effectiveness of HIV
interventions in prisons. At one session, Dr
Andrew Ball from WHO presented a summary of
the main conclusions and recommendations
reached by the review, which will soon be published as part of the WHO "Evidence for Action"
papers series.2 The review contains the most
detailed and rigorous analysis of the evidence
related to HIV/AIDS in prisons undertaken to
date. In his presentation, Dr. Ball pointed out
that sexual activity within prisons has been
reported from around the world; that studies in
several nations have shown that injecting drug
use is also a reality in many prisons; that even
countries that have invested heavily in drug
demand and drug supply reduction efforts in
prisons have not been able to stop injecting
drug use; and that outbreaks of HIV infection
have been documented in a number of prison
systems, demonstrating how rapidly HIV can
spread in prison unless effective action is taken
to prevent transmission. He went on to say that
HIV programs in prisons often exclude necessary interventions for which evidence of effectiveness exists, and that there is an urgent need
to introduce more comprehensive programs.
Condom Provision
Dr. Ball reported that the available research and
the experience of many prison systems in different parts of the world in which condoms are provided to prisoners suggest that providing condoms in prisons is feasible in a wide range of
prison settings. No prison system allowing condoms has reversed its policy on condom provision, and none has reported security problems
or any other relevant major negative consequences. In particular, it has been found that
condom access is unobtrusive to the prison routine, represents no threat to security or operaContinued on page 3
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Dear Corrections Colleagues,
For the past two decades, people from around the globe involved in the fight to combat the HIV/AIDS pandemic have gathered at two-year intervals at the International AIDS Conference (IAC). Like attendees at typical scientific meetings they trade data and share lessons learned. But those coming to an IAC also know well
that there will be much more than PowerPoint presentations to see as clinicians, scientists, activists, industry
representatives and policy makers mix and, at times clash as they debate strategies, set policies and launch
initiatives to advance HIV treatment and prevention. Past conferences have served as watershed events in
the history of HIV/AIDS ushering in the era of HAART in 1996 and focusing the world's attention on AIDS in
developing countries in 2000.
The International AIDS Conference (IAC) held in Toronto in August was attended by almost 30,000 people and
focused on the urgent need to deliver the promise of therapeutic and preventive advances to those affected
by HIV/AIDS. A thread running through much of this conference was the plight of those living with HIV infection and incarcerated in our prisons and jails. During plenary sessions on global AIDS epidemiology, keynote
speeches by policy makers and activists and in oral sessions on HIV transmission prevention, the role of incarceration in the spread of HIV and the need to provide quality HIV therapy to those imprisoned was featured.
Two sessions of oral presentations were actually dedicated to this theme, reflecting the emergence of incarceration as an item on the agenda of the HIV treatment/prevention communities.
Ralf Jurgens, an IDCR board member, member of the IAC Scientific Committee and a Canadian himself,
reports on presentations centering on the nexus between HIV and incarceration. In his report he provides a
look at approaches to HIV transmission prevention in prisons and jails that have been explored largely outside the U.S. Some of the strategies he presents, such as those advanced by the World Health Organization
(WHO), are controversial and provoke strong responses regarding feasibility and safety. Such responses are
expected and, indeed, healthy. The IAC is a platform for the presentation of data that others can use and
adapt to meet the needs of those they serve, what works in Moldova may not work in Mississippi but it may
be of interest to a jailer in Miami. No matter where you are, join the debate by emailing your letter to editor
to me at wohl@med.unc.edu or Anne Degroot at Anne_Degroot@brown.edu
Data on HIV therapeutics could also be found in Toronto and the major clinical trials findings are included in
an article accompanying Ralf's report. You will also find a summary of the recent Institute of Medicine report
on the ethics of research in prisons - an important report that will have considerable impact on the conduct of
research studies in correctional settings
Lastly, while we were going to press the Centers for Disease Control and Prevention (CDC) made their longawaited announcement regarding changes to their HIV testing recommendations. These changes include
vastly expanding HIV testing and removal of separate written consents and extensive pre-test counseling considered obstacles to testing. These new recommendations will have tremendous implications for HIV
screening in correctional facilities and will be covered in detail in our next issue.
Sincerely,
David Alain Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Trials Unit
The University of North Carolina - Chapel Hill

David Paar, MD
Associate Professor of Medicine,
University of Texas, Medical Branch
Dean Rieger, MD
Officer/Corporate Medical Director,
Correct Care Solutions
Karl Brown, MD, FACP
Infectious Disease Supervisor
PHS-Rikers Island
Ralf Jürgens
Consultant
Joseph Paris, PhD, MD, FSCP, CCHP
Former Medical Director,
Georgia Dept. of Corrections
Lester Wright, MD, MPH
Chief Medical Officer,
New York State Dept. of Correctional Services
William Cassidy, MD
Associate Professor of Medicine,
Louisiana State University Health Sciences
Center

Bethany Weaver, DO, MPH
Acting Instructor, Univ. of Washington,
Center for AIDS and STD Research
David Thomas, MD, JD
Professor and Chairman,
Division of Correctional Medicine
NSU-COM
Editorial Board
Neil Fisher, MD
Medical Director, Chief Health Officer,
Martin Correctional Institute

Louis Tripoli, MD, FACFE
Vice President of Medical Affairs, CMS
Correctional Medical Services

____ Yes, I would like to add/update/correct (circle one) my contact information for my complimentary
subscription of IDCR fax/email newsletter.
____ Yes, I would like to sign up the following colleague to receive a complimentary subscription of
IDCR fax/email newsletter.
____ Yes, I would like my IDCR to be delivered in the future as an attached PDF file in an
email (rather than have a fax).

FACILITY:

Physician Assistant
Medical Director/Administrator

CITY:

FAX:

PHONE:

Steven F. Scheibel, MD
Regional Medical Director
Prison Health Services, Inc
Mary Sylla
Director of Policy and Advocacy,
Center for Health Justice

Eric Avery, MD
Associate Clinical Professor of Psychiatry
University of Texas, Medical Branch

Nurse/Nurse Practitioner
HIV Case Worker/Counselor

ADDRESS:

Josiah Rich, MD
Associate Professor of Medicine and
Community Health
Brown University School of Medicine

Barry Zack, MPH
Executive Director, Centerforce

CHECK ONE:

EMAIL:

Associate Editors
Rick Altice, MD
Yale University AIDS Program

Michael Poshkus, MD
Medical Program Director, Rhode Island
Department of Corrections

Fax to 401-272-7562 for any of the following: (please print clearly or type)

Physician
Pharmacist

In accordance with the Accreditation Council for Continuing
Medical Education Standards for Commercial Support, the
faculty for this activity have been asked to complete Conflict
of Interest Disclosure forms. Disclosures are listed at the
end of articles.

Lynn Taylor, MD
Assistant Professor of Medicine, Brown University
School of Medicine, The Miriam Hospital

Subscribe to IDCR

NAME:

2

visit IDCR online at www.IDCRonline.org

Vol. 9, Issue 9

STATE:

Nurse Administrator
Other

ZIP:

Jim Montalto
The Corrections Connection
Layout
Jose Colon
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor
Elizabeth Closson
IDCR

September 2006

Vol. 9, Issue 9

tions, does not lead to an increase in sexual activity, and is accepted by most prisoners and correctional officers once it is introduced. Generally, only minor incidents of
misuse such as water balloons, water fights
and littering were recorded.
Studies have not determined whether infections have been prevented due to condom
provision in prison. However, data from a
variety of settings have documented the
effectiveness of condoms in preventing
sexually transmitted infections and there is
evidence that prisoners use condoms to
prevent infection during sexual activity
when they are accessible. Evidence suggests that condoms are more likely to be
used if they are easily and discreetly accessible so that they can pick them up at various locations in the prison, without having
to ask for them and without being seen by
others.
Needle and Syringe Programs
The first prison needle and syringe program
(NSP) in the world was established in
Switzerland in 1992. Since then, NSPs
have been introduced (or are about to be
introduced) in various prison environments
in 11 countries in Western and Eastern
Europe and in Central Asia.
Systematic evaluations of the effects of
NSPs on risk behaviors and of their overall
effectiveness in prisons were carried out in
at least 10 projects in Switzerland,
Germany, and Spain. According to Dr. Ball,
there is evidence that NSPs are feasible in
a wide range of prison settings, including in
men's and women's prisons, prisons of all
security levels, and small and large prisons.
There is also evidence that providing clean
needles and syringes is readily accepted by
injecting drug users in prisons and may
contribute to a significant reduction of
syringe sharing over time. It also appears to
be effective in reducing resulting HIV infections.3-6 At the same time, there is no evidence to suggest that prison-based NSPs
have serious, unintended negative consequences. In particular, the WHO report
states that they do not appear to lead to
increased drug use or injecting, and needles have not been used as weapons.
Evaluations have found that NSPs in prisons actually facilitate referral of drug users
to drug dependence treatment programs.
Methadone Maintenance Treatment (MMT)
A wealth of scientific evidence has shown
that, in the community, MMT is the most
effective intervention available for the treatment of opiate dependence. MMT has been
shown to be effective in improving the
physical and social wellbeing of the patient
and has been associated with reductions in
risk behavior, illegal drug use, criminal
behavior, participation in sex work, unemployment, mortality, and HIV transmission.
Dr. Ball reported that, more recently, a substantial body of research has delivered significant findings regarding the effectiveness

visit IDCR online at www.IDCRonline.org
and acceptability of MMT in prison settings:
Adequate prison-based MMT pro
grams appear to be effective in reducing
injecting drug use and associated needle sharing.
Prisoners need a daily dose of at least
60 mg of methadone and treatment is
generally required for the duration of
incarceration for these benefits to be
realized in prison.
Adequate prison-based MMT programs
have additional and worthwhile benefits:
MMT in prison significantly facilitates entry and retention in postrelease treatment compared to prisoners enrolled in detoxification programs;
Re-incarceration is significantly less
likely among those prisoners who
receive MMT while incarcerated;
MMT has a positive effect on institutional behavior by reducing drugseeking and thus improving prison
safety;
Although prison administrations
often initially raise concerns about
security, violent behavior, and diversion of methadone, these problems
do not emerge once the MMT program is implemented.
MMT may help to reduce risk of overdose for those nearing release.
There is evidence that people who are
on MMT and who are forced to withdraw
from it because they are incarcerated
often return to narcotic use, often within
the prison system, and often via injecting. Therefore, particular efforts are
needed to ensure that prisoners on
MMT prior to imprisonment are able to
continue this treatment while in prison.
Other Forms of Drug Dependence
Treatment
Dr. Ball pointed out that, in contrast to MMT,
other forms of drug dependence treatment
have not usually been introduced in prison
with HIV prevention as one of their objectives. There is, therefore, little data on the
effectiveness of these forms of treatment
as an HIV prevention strategy. However,
good quality, appropriate, and accessible
treatment has the potential of improving
prison security, as well as the health and
social functioning of prisoners, and it can
reduce reoffending. Such treatment in
prison can help reduce the amount of drug
use in prisons and upon release. But there
is a need for independent and systematic
outcome evaluations of these interventions,
and for examining their effectiveness in
reducing injecting drug use and needle
sharing.
Alternatives to Imprisonment
Ultimately, Dr. Ball said, research suggests
that reducing the number of people who are
in prison because of problems related to

3

their drug use must be a priority. Studies
have shown that fear of arrest and sanctions is not a major factor in an individual's
decision on whether to use or deal drugs;
and that there is little correlation between
incarceration rates and drug use prevalence in particular countries or cities. As
early as 1987, WHO, in a statement from
the first Consultation on Prevention and
Control of AIDS in Prisons, said that
"[g]overnments may … wish to review their
penal admission policies, particularly where
drug abusers are concerned, in the light of
the AIDS epidemic and its impact on prisons."
Prevention in Action: Examples from
around the World
Other presentations at AIDS 2006 focused
on how HIV prevention measures have
been introduced in practice in prison environments around the world:
Morag MacDonald presented work undertaken in Ukraine to move from evidence
about HIV transmission in prison to implementation of HIV prevention measures,
notably needle and syringe programs.7 In a
study conducted in 2005 in seven prisons in
five regions of Ukraine among 831 prisoners, between 16% and 32% of prisoners
tested HIV-seropositive, and 75.5 and
91.5% of prisoners tested HCV seropositive in the two prisons in which HCV testing
was also undertaken.
In addition, an HIV transmission cohort
study in two prisons showed that six cases
of HIV infection occurred between
December 2004 and August 2005 among
the 276 prisoners who were still in the
cohort in August 2005. Initially, 400 who
were in prison for more than six months
were recruited to participate in the study. In
order to assist the Ukrainian prison system
with the implementation of HIV prevention
measures in prisons, a partnership was
struck between the Ukrainian prison system, a number of Ukrainian non-governmental organizations (NGOs), and the
Canadian HIV/AIDS Legal Network. As a
result of a number of joint activities, including trainings of senior staff and prison study
tours with existing prevention programs,
the initial resistance to implementation of
pilot needle and syringe projects was overcome, and projects were scheduled to start
in 2006. However, the elections in Ukraine
and the following long period of political
uncertainty have delayed the implementation of the pilot projects.
Anak Agung Gede Hartawan from
Kerobokan Prison in Bali, Indonesia,
described how the prison introduced the
first MMT program in a prison in
Indonesia.8 Currently, 32 of 785 prisoners
receive MMT and the program will soon be
expanded to other prisons. If medically indicated, prisoners are allowed to start MMT
in prison. Other prisoners are allowed to
Continued on page 4
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continue such treatment started in the community. In addition to MMT, condoms and
bleach are also available in the prison.
Dumitru Laticevschi from Moldova explained
how a comprehensive prevention program
(including provision of condoms, bleach,
needle and syringe programs, and MMT)
was introduced in prisons in his country, and
how this program has contributed to preventing further spread of HIV among prisoners
and, ultimately, to the general community.9
HIV Care, Treatment, and Support
Presentations from a number of countries at
AIDS 2006 showed that providing HIV therapy for prisoners is a challenge, but is necessary and feasible. The WHO review of existing studies, many of who were undertaken in
the United States, showed:
When provided with care and access to
medications, prisoners respond well to
antiretroviral treatment.
Adherence rates in prisons can be high
as or higher than that among patients in
the community. This is also true for injecting drug users, particularly when they can
access MMT.
However, the gains in health status
made during the term of incarceration
may be lost unless careful discharge
planning and linkage to community care
are undertaken.
Presenters at the conference highlighted
that, as ART is increasingly becoming available in developing countries and countries in
transition, it will be critical to ensure that it
also becomes available in the countries' correctional systems. Ensuring continuity of
care from the community to the prison and
back to the community, as well as continuity
of care within the jail/prison system, is a fundamental component of successful treatment
scale-up efforts. Presentations from four
countries in Africa highlighted the many
obstacles that exist to treatment access in
prisons in Africa. Jonathan Berger from
South Africa talked about the efforts his organization, the AIDS Law Project, is undertaking to ensure access to treatment in prisons,
partly through litigation against the South
African Department of Correctional Services,
which has to date failed to provide adequate
access to ART.10 Alick Nyirenda from
Zambia reported about a campaign that
started in 2005 to offer voluntary HIV counseling and testing, as well as care and treatment, to prisoners. Of the first 100 prisoners
tested, 64 tested HIV positive, and 15 were
commenced on ART.11 At the satellite meeting organized by the UN Office on Drugs and
Crime, the Public Health Agency of Canada
and the Correctional Service of Canada, presenters from Nigeria12 and Kenya13 also discussed the barriers they faced and the
efforts they have undertaken to scale up
access to HIV counseling and testing and to
treatment.
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Giving a Voice to (Former) Prisoners
For the first time at an International AIDS
Conference, delegates were able to hear not
only from researchers and staff working in
prisons, but also from former prisoners, who
are experts on HIV/AIDS in prisons because
they live with the disease, know fellow prisoners living with HIV, know what risk behaviors prisoners engage in, and whether or not
existing efforts respond to their needs and
make a difference. James Motherall, a former prisoner and peer health worker in a federal prison in Canada, said that "the fight
against AIDS will not be won until we can
reach out to those we are angriest at, until
we can extend to our prisoners the same
compassion, human rights and dignity that
we are prepared to extend to others".14
Connor McCollum, another former prisoner
talked about the experience of prisoners living with and/or at risk of HIV and HCV in
Canadian prisons.15 Finally, Igor Sobolev
from Estonia presented the work of an NGO
that has been active since 2002 in prisons,
providing support to HIV-infected drugdependent prisoners.16
What about the United States?
At previous conferences, research on
HIV/AIDS in prisons from the United States
had often been presented in oral sessions. At
AIDS 2006, only a number of poster presentations highlighted new developments and
findings from the United States. This was
due to two factors:
The effort made by conference organizers to include more research from developing and transitional countries, particularly in Africa, Eastern Europe and SouthEast Asia, which are facing serious
HIV/AIDS epidemics in prisons; and
The fact that, increasingly, the United
States are seen by international experts
as lagging behind other countries in the
provision of evidence-based prevention
interventions in prisons.
On the other hand, researchers in the United
States continue to do cutting-edge research,
including on interventions to improve access
to care, reduce transmission risk behavior
and recidivism in HIV-infected prisoners following release. Two posters presented preliminary results of the BRIGHT study, a randomized control trial in HIV-infected state
prison inmates in North Carolina of a
Strengths-Based Model of case management designed to bridge incarceration and
release (versus standard discharge planning
conducted prior to release only). Preliminary
data indicate that a case management intervention for HIV-infected prisoners spanning
the periods prior to and after prison release
is successful in increasing access and utilization of HIV medical care, reducing emergency room utilization, and reducing early
recidivism.17 Interviews with participants in
the study six months after release showed
that for HIV-infected prisoners, release is a

time associated with great emotion and anxiety, particularly with respect to substance
abuse and family relationships. This confirms
that more intensive release preparation programs spanning the continuum of both preand post release are needed, and that these
programs should not only provide HIV-related care and support services, but a broader
spectrum of support including substance
abuse prevention and treatment and community supports.18
New Resources
A final important development at AIDS 2006
was the release, by three UN agencies (the
UN Office on Drugs and Crime, the World
Health Organization, and UNAIDS), of
"HIV/AIDS Prevention, Care, Treatment and
Support in Prison Settings: A Framework for
an Effective National Response".19
Consistent with the message of the sessions
and presentations at the conference, the
document emphasizes that "good prison
health is good public health," saying that "the
vast majority of people committed to prison
eventually return to the wider society" and
that "therefore reducing the transmission of
HIV in prisons is an important element in
reducing the spread of infection in society
outside of prisons." The document also highlights that "protecting and promoting the
health of people in prison benefits not only
the prisoners, but also increases workplace
health and safety for prison staff."
The document stresses, "people in prison
are entitled, without discrimination, to a standard of health care equivalent to that available in the outside community, including preventive measures." It calls upon decisionmakers "to acknowledge that high risk
behaviors for the transmission of HIV occur
within prisons - especially injecting drug use,
sexual activity, and sexual abuse/violence and to base decisions affecting prison health
on evidence, recognized best practice, and
legal and ethical obligations, rather than on
public opinion or political expediency." It recommends implementation of comprehensive
HIV/AIDS prevention and education (including condoms and sterile needles and
syringes), voluntary counseling and HIV testing, HIV/AIDS care and treatment for prisoners, and drug dependence treatment programs in prisons.
Read the op-ed by Dr. Lester Wright in
response to the WHO recommendations at
www.idcronline.org

Go to www.AAHIVM.org to learn about membership, continuing education and the new partnership with IDCR
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The International AIDS Conference (IAC) is
increasingly becoming a global forum for
the presentation of data and information
related to the prevention of HIV infection as
well as the effects of the disease on the
lives of those with HIV/AIDS. Advances in
knowledge about HIV pathogenesis and
therapeutics have taken a back seat to the
pressing social and behavioral dimensions
of the epidemic and are now the focus of
several smaller conferences and meetings.
However, for those with patience, the XVI
International AIDS Conference held in
Toronto held a few clinical trial gems - most
presented on the final day of the conference during the late breaker session. The
major findings likely to have implications for
the management of HIV-infected individuals in and out of prison/jail are summarized
below.
Initial HIV Therapy
Efavirenz (Sustiva) versus Lopinavir/Rito navir (Kaletra) The non-nucleoside reverse
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transcriptase inhibitor (NNRTI), efavirenz
and the protease inhibitor (PI) co-formulated drug lopinavir/ritonavir are each
anchors of the regimens listed as 'preferred' in the US Department of Health
and Human Services (DHHS) guidelines
for initial therapy of HIV infection. 1 Both
drugs are popular but in many ways these
are very different agents. Beyond their
disparate targets, they differ in pill count,
side effects and cost. However, they
share an accumulation of clinical trial data
that demonstrate their relative potency in
suppressing HIV replication long term.
How they stack-up against one another,
though, has not been clear.

trial results, few did so correctly. The times
to virologic failure and regimen completion
were shorter with lopinavir/ritonavir than
with efavirenz and the proportion of participants with a viral load below 50 copies/mL
at 96 weeks was 89% for efavirenz, 77%
for lopinavir/ritonavir and 83% for the combination (the comparison between
efavirenz and lopinavir/ritonavir was statistically significant, p = 0.003). The differences between the arms were not as
marked when looking at the proportion with
viral loads less than 200 copies/mL with
more patients in the lopinavir/ritonavir arm
having viremia between 50 and 200
copies/mL.

The US AIDS Clinical Trials Group (ACTG)
launched study A5142 to compare these
antiretroviral behemoths.2 A total of 753
patients on antiretroviral (ART) were randomized to one of three arms: a) two nucleoside reverse transcriptase inhibitors
(NRTIs) plus efavirenz; b) two NRTIs plus
lopinavir/ritonavir or c) efavirenz plus
lopinavir/ritonavir (a novel NRTI-sparing
approach). The choice of NRTIs in the first
two arms was left to the discretion of the
local investigator. The study endpoints
included virologic failure (lack of a ten-fold
decline in HIV viral load or viral rebound
during first 32 weeks of the study or failure
to reach a viral load below 200 copies/mL
after week 32) and regimen completion
(treatment discontinuation for virologic failure or toxicity related discontinuation of
regimen component).

The sound of the proverbial other shoe
dropping came from the resistance data.
While efavirenz and two NRTIs performed
the best virologically, the few participants
that did fail this combination were more
likely to have drug resistance than those
experiencing failure in the lopinavir/ritonavir. Of those who were treated with
efavirenz and experienced failure, half had
evidence of NNRTI resistance and a third
had NRTI resistance detected. In contrast,
relatively few subjects in the lopinavir/ritonavir group who had virologic failure had
detectable resistance mutations (15%
NRTI, 4% NNRTI and 0% PI resistance). In
addition, despite the virologic results, CD4+
cell count increases were overall greater
during treatment with lopinavir/riotnavir
than efavirenz (268/mm3 versus 241/mm3,
p = 0.01).

While many thought they could predict the

Continued on page 6
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Limited toxicity data were presented but the
three regimens appeared to be similarly
well-tolerated;
however,
hypertriglyceridemia above 750 mg/dL was observed in
14% of the NNRTI/PI arm but only 3-6% of
those of those in the other two arms.
These important results suggest that virologic suppression to below the limits of assay
detection are more likely with an initial regimen containing two NRTIs plus efavirenz
than two NRTIs and lopinavir/ritonavir. The
trade-off when using dual NRTIs and efeavirenz may be a greater risk of drug resistance among the few that do experience
virologic break through and a slightly lower
CD4+ cell count response. Further data on
lipids and body shape will be forthcoming
and will likely help to complete the comparison between these two treatment approaches.
Tenofovir/Emtricitibine (Truvada) versus
Zidovudine/Lamivudine (Combivir)
After deciding whether to use a PI or an
NNRTI, the clinician initiating HIV therapy
must then choose which NRTIs to add to the
mix. Combination formulations of NRTIs
have reduced pill count and are a popular
choice.
Both
tenofovir/emtricitabine
(TDF/FTC) and zidovudine/lamivudine
(ZDV/3TC) are included in the DHHS guideline for first line use and their relative efficacy and tolerability are being studied in a
study sponsored by the maker of TDF/FTC,
data from which was presented at the IAC.3
This is an open-label, 144-week trial in
which 255 treatment-naïve patients were
randomly assigned to open-label TDF/FTC
plus efavirenz or ZDV/3TC plus efavirenz.
Previously, the 48-week data were
announced and demonstrated that the proportion of participants with a viral load less
than 50 copies/mL at that time point was significantly higher among those receiving
TDF/FTC. Importantly, failure was defined
using the FDA standard for efficacy, time to
loss of virologic response (TLOVR), which
requires virologic suppression and no treatment-limiting toxicity. At 48 weeks, adverse
effects among those assigned ZDV/3TC
largely drove the difference between study
arms - given efficacy was judged using the
TLOVR composite endpoint.
In Toronto, an update of the data at 96
weeks indicate that the differences between
the arms have narrowed with no significant
difference in the proportion with a viral load
less than 50 copies/mL observed between
the arms using the TLOVR criteria for failure.
However, there was a significant difference
in the proportion with a viral load below 400
copies/mL - the main outcome of the study favoring TDF/FTC (75% in TDF/FTC arm
versus 62% in ZDV/3TC arm less than 400
copies/mL at week 96, p = 0.004). In addition, mean CD4+ cell count increases were
greater in the TDF/FTC arm versus the
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ZDV/3TC arm (270/mm3 versus 237/mm3,
p=0.036). Again, treatment-limiting toxicity,
particularly anemia, was responsible for the
relatively poorer performance of ZDV/3TC
as the two regimens performed equally
when only the viral suppression was considered.
Renal function was followed during the study
using several measures including serum
creatinine and estimations of glomerular filtration rate (GFR) and creatinine clearance
(CrCl). Serum creatinine was not observed
to significantly change; however, this is considered a crude assessment of renal health.
CrCl as calculated by the Cockcroft-Gault
equation did not demonstrate a significant
difference between arms during the study; a
statistically significant decrease in GFR during TDF/FTC treatment was detected using
the Modification of Diet in Renal Disease
(MDRD) equation. This difference was small
(decline from 110 to 100 mL/min/1.73m2 in
TDF/FTC arm versus gain of 3
mL/min/1.73m2 in the ZDV/3TC arm, [p
=0.006]) and remained stable during the
course of the study. The Cockcroft-Gault
equation includes weight while the MDRD
does not but does consider race as a variable. Note, patients had to have relatively
normal renal function to be eligible for participation in this study. As previously demonstrated, DEXA assessed limb fat was seen
to decline in the ZDV/3TC group compared
to a gain in limb fat in the TDF/FTC subjects.
Resistance testing revealed that in both
arms, mutations to efavirenz was most common among those with virologic failure, followed by resistance to FTC and 3TC. Thus
far, the K65R mutation, which confers broad
NRTI resistance and has been associated
with tenofovir, was not seen with either study
treatment.
Simplifying Therapy
Interest in simplifying combination HIV therapy has existed almost as long as there has
been a three-drug antiretroviral cocktail.
Early forays into induction-maintenance
strategies produced inconsistent results but
with the advent of potent ritonavir-boosted
PIs, there have been renewed efforts to distill HAART to a simple regimens - including
single drug treatment. Several presentations
at the conference examined use of
lopinavir/ritonavir as single agent therapy. In
one study, lopinavir/ritonavir along with
ZDV/3TC was administered to 104 treatment-naïve patients and those who
achieved a viral load less than 50 copies/mL
by three months then had the NRTIs
removed.4 Compared to a control arm
receiving ZDV/3TC plus efavirenz, there was
no significant difference in virologic suppression below 50 copies/mL at week 96
between the strategies and, interestingly,
low level viremia was more commonly seen
with lopinavir/ritonavir. In another study, 200
patients with suppressed HIV viremia on
HAART were randomly assigned to
lopinavir/ritonavir
monotherapy
or
lopinavir/ritonavir plus ZDV/3TC.5 Again, at

48 weeks there was no difference in the proportion of subjects in each arm with a viral
load less than 50 copies/mL. Lastly, upping
the monotherapy ante, French investigators
assigned treatment-naïve patients to
lopinavir/ritonavir alone or lopinavir/ritonavir
plus ZDV/3TC. 6 In the intent-to-treat analysis the study arms produced rates of viral
suppression below 50 copies/mL that were
not significantly different. However, an ontreatment analyses demonstrated higher
rates of low level viremia in the monotherapy arm. In all three studies, PI resistance
during monotherapy was observed in a proportion of those with virologic failure in
whom genotype testing was performed
strongly suggesting that there is a small but
important risk of resistance with this minimalist approach.
Monotherapy with a boosted PI holds many
attractions but there are risks, as these studies demonstrate, namely increased rates of
low level viremia and the possibility of PI
resistance. Investigation of boosted PI
monotherapy continues, and studies of other
agents are ongoing (see News and
Reviews). These will help define the role of
boosted PI monotherapy. Until then, this is
an approach that must be considered investigational.
The Treatment-Experienced Patient
For patients harboring a drug resistant virus,
drugs able to suppress such viral strains are
often desperately needed.
The recent
approval of agents active against drug resistant HIV, particularly tipranavir (Aptivus) and
darunavir (Prezista), are important developments in the management of HIV disease
and hold out hope for treatment-experienced
patients. Updated 48 week data from two
large trials of darunavir, POWER 1 and 2
were presented at the IAC.7 Both POWER 1
and 2 studied patients with triple ARV class
experience (mean number of PI mutations
was three), at least one PI mutation and an
HIV RNA level >1,000 copies/mL. The aim of
both studies is to determine the optimal dose
of the darunavir and its efficacy compared to
an investigator selected ritonavir-boosted PI
when both were included with optimized
ARV regimens using existing drugs informed
by resistance testing. In an analysis combining subjects from these two similar studies which compared responses among 131
subjects receiving 600 mg/100 mg of
darunavir/ritonavir BID twice daily (the US
FDA approved dose) and 124 on an optimized regimen alone, 46% of those
assigned darunavir/ritonavir and 10% of the
controls achieved a viral load of less than 50
copies/mL at 48 week (p = 0.001). The
mean CD4 cell count increase was 102/mm3
versus 19/mm3 for the darunavir/ritonavir
and control arms, respectively (P < 0.005).
Darunavir/ritonavir was well tolerated without excess toxicity relative to the control
arm.
Data were also presented on many of the
new agents coming down the pike or already
Continued on page 7
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pulling into the driveway. Results demonstrating the antiviral activity of TMC-125, an
NNRTI with activity against NNRTI-resistant
HIV strains8; MK-0518, the first integrase
inhibitor that will likely come to market9; the
CCR5 inhibitors vicriviroc and maraviroc
10,11 and the maturation inhibitor TNX-35512
were presented and justify an optimistic perspective on the future of HIV therapy.

to spot celebrities. While the conference
has shifted away from therapeutics, the few
clinical trial data presented this year did
advance our understanding of the abilities of
existing drugs and introduced us to hopeful
newer agents. These results had a tough
time competing for attention with the
speeches by notables and the coverage of
the more sensational aspects of the conference, but are of great importance to the
enhancement of our care of HIV-infected
persons in our correctional facilities.

Conclusions
The IAC is like no other conference. It is big,
boisterous, political and a great opportunity
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SPOTLIGHT - HEALTH THROUGH WALLS, SUSTAINABLE PRISON HEALTHCARE
COUNTRIES: AN INTERVIEW WITH JOHN MAY, MD
Elizabeth Closson
IDCR Managing Editor
Disclosure:
EC - Nothing to disclose. JM - Speaker's
Bureau: Abbott Laboratories, Boehringer
Ingelheim, Bristol-Myers Squibb, Gilead
Sciences.
Elizabeth Closson (EC): What is your current job?
Dr. John May (JM): I am Chief Medical
Officer for Armor Correctional Health
Services, based in Coconut Creek, Florida.
We provide comprehensive health care
services at several jails in Florida and a few
prisons in Virginia. I am also an Associate
Clinical Professor at NOVA Southeastern
College of Medicine. In 2005, I founded
Health through Walls, a non-profit organization of U.S.-based correctional health
care professionals providing volunteer consultation and assistance to prison health
care programs in developing countries.
EC: How would you describe your volunteer activities overseas with correctional
institutions?
JM: Nearly every two months since 2001,
we have provided patient care, resources,
staff training, or consultations inside the
Caribbean prisons of Haiti, Dominican
Republic, or Jamaica. In addition we work
in the African countries of South Africa,
Tanzania, and Ghana. U.S. doctors, nurs-
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es, and others with correctional experience
donate their time, travel at their own
expenses, and collect and deliver needed
materials to the prison programs. Our primary focus is the screening, prevention,
and treatment of infectious disease, particularly HIV and tuberculosis. Our role is to
guide and be in solidarity with prison health
staff, build sustainable alliances within the
community, and advocate for our patients.
EC: How did you get involved in providing
help to overseas correctional institutions?
JM: I think it's natural for many correctional
health care professionals to extend themselves to the underserved and disenfranchised and also to recognize that managing
prison health and infectious disease is
essential to public health. Health through
Walls began as a personal quest to do just
that, and has grown as countries learn of
our work and request our services.
EC: What do you think the most pressing
needs are in the countries you visit?
JM: It begins with a political and cultural
commitment to recognize the humanity and
dignity of incarcerated persons. This
includes a commitment to the rights of the
individual, including health, and the allotment of adequate resources for the population. In the countries in which we operate,
some prisons struggle and fail to provide
adequate nutrition and clean water. Many
are so overcrowded that infectious dis-
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eases flourish. All need improved access
to diagnostic services and medications,
particularly antiretrovirals. Prisoners are
dying because they cannot access treatment.
EC: How could other providers get more
involved?
JM: The American Correctional Association
has a project to deliver donations to prison
systems of developing countries.
They
can facilitate contributions of equipment
and supplies. Health through Walls needs
clinicians, evaluators, diagnostic equipment, technical support, and unexpired
medications especially antiretrovirals.
Providers can contact me if they have
something to contribute by email atjmay@armorcorrectional.com.
EC: What lessons have you learned
through your volunteer activities that have
applied to your domestic work?
JM: I never let a supply or medication go to
waste or be used unnecessarily. I've
gained admiration for the diagnostic skills
and clinical judgment of clinicians practicing in settings of limited resources. And
I've been inspired by the stronger emphasis
in many countries on rehabilitation, openness to harm reduction measures, and
keeping the prisoner more closely connected to family and community. Not surprisingly, they don't have the same high level of
recidivism as we do.
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Countries
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Institute of Medicine' 2006 Ethical Considerations for Research Involving
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2003 Department of Health and Human Services Office for Human
Research Protections Guidelines on the Involvement of Prisoners in
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RESULTS AT 96 WEEKS OF A5142 - A RANDOMIZED STUDY OF INITIAL HIV THERAPY WITH
LOPINAVIR/RITONAVIR ALONG WITH TWO NRTIS OR THE COMBINATION OF THE TWO ALONE.
LPV/r
(n=253)

EFV
(n=250)

LPV/r+EFV
(n=250

% <50 HIV copies/mL (ITT)

77 %

89 %

83 %

0.003

% <200 HIV copies/mL (ITT)

86 %

93 %

92 %

0.041

% Without virologic failure*

67 %

76 %

73 %

0.006

% Without regimen completion due to virologic failure or toxicity**

54 %

60 %

61 %

0.02

CD4+ cell count change from baseline (/mm3)

+285

+241

+268 %

0.01

NRTI
M184V
K65R

8 (15%)
7
0

11 (33%)
8
3

4 (10%)
1
0

NNRTI
K103N

2 (4%)
0

16 (48%)
9

27 (69%)
21

0

0

2

6%

3%

14 %

P Value
LPV/r vs. EFV

Genotypic resistance mutations detected [#
subjects (% genotypes in that arm)]:

Major PI (IAS guidelines)
% Fasting triglycerides >750 mg/dL

Not Reported

Not Reported

Modified from: Riddler S, et al. IAC 2006. Abstract THLB0204

LPV/r = Lopinavir/ritonavir, EFV = Efavirenz, ITT = intent-to-treat analysis with missing considered a failure, NRTI = nucleoside reverse transcriptase
inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = protease inhibitor. IAS = International AIDS Society
*Virologic failure defined as a) lack of 1 log10 drop in viral load or rebound before week 32 or b) failure to suppress to <200 copies/mL or rebound
after week 32. Threshold for statistical significance p <0.016.
**Regimen completion defined as virologic failure or toxicity related discontinuation of any regimen component. Threshold for statistical significance p
<0.016.

SPECIAL REPORT
In June of 2006 the Institute of
Medicine (IOM) issued a report entitled Ethical Considerations for
Research Involving Prisoners. The
report documents the recommendations of an IOM committee commissioned by the Office of Human
Research Protections (OHRP) of
the Department of Health and
Human Services (DHHS), to review
the ethical considerations in
research involving prisoners. The
report will serve as the guideline for
the updated prisoner protection regulations set forth by the DHHS. The
committee contends that while the
OHRP's jurisdiction is inherently limited, its enforcement of codified
oversight should be strengthened.
The recommendations found in the
report should therefore be imposed
on all governmental and privately
funded research. See IDCR-OGRAM for a summary of the IOM's
Ethical Considerations for Research
Involving Prisoners report.

IDCR-O-GRAM - Summary of the IOM's
Ethical Considerations for Research Involving Prisoners report.
Recommendations
Expanded Definition of “Prisoner”

Consistent Ethical Protection

Risk-Benefit Approach

Collaborative Responsibility

Increased Systematic Oversight

Details
In the OHRP (Office of Human Research
Protections) regulations, the term "prisoner" will
include inidividuals on parole and probation.
All publicly and privately funded research will be subject to the same ethical regulations. A national, publicly accessible registry of all research involving prisoners should be created.
All research proposals require a risk-benefit assesment. The potential benefits to prisoners must
out number the risks for the research to be considered permissible. In biomedical research only
personal benefits will be taken into consideration
given the inherent risk of the research. Prisoners
cannot make up more than 50% of the subject
population in any given biomedical research project.
Research should be tailored to fit the specific
needs of the correctional setting, facilitating
greater collaboration between researchers and
the correctional facility.
Unbiased prison research subject advocates should
monitor all research activity. The greater the
research's risk and the more confined the correctional setting, the stricter the ethical guidelines.

Ethical Considerations for Research Involving Prisoners.
Institute of Medicine. 2006. Available at http://www.iom.edu/CMS/3740/24594/35792.aspx
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SAVE THE
DATES
44th Annual Infectious Diseases
Society of America (IDSA) Conference
October 12-15th, 2006
Toronto, Ontario, Canada
Visit: www.idsociety.org
"Managing Addiction in the HIV-infected Patient"
Live Satellite Video Conference
Part of Management of HIV/AIDS in the
Correctional & Community Setting
October 18, 2006
Albany Medical College 12:30-2:30
CME & CNE credits available
Visit: www.amc.edu/HIVConference
E-mail: ybarraj@mail.amc.edu
Phone: 518.262.4674
Infectious Disease in Corrections
Report (IDCR) Symposium
"Managing Infectious Disease: An Expert
Panel"
Pre-conference before the NCCHC
Conference
Saturday Afternoon, October 28, 2006
CME credits available
Hyatt Regency Hotel Atlanta, GA
Visit:http://www.ncchc.org/education/nati
onal2006/atlanta.html
57th Annual Meeting of the American
Association for the Study of Liver
Diseases
October 27-31, 2006
John B. Hynes Convention Center
Boston, MA
Visit: https://www.aasld.org/eweb/
DynamicPage.aspx?webcode=06_Liver
meeting
National Commission on Correctional
Health Care (NCCHC) Conference
October 28- November 1, 2006
Hyatt Regency Hotel Atlanta, GA
Visit:http://www.ncchc.org/education/nati
onal2006/atlanta.html
134th Annual American Public Health
Association (APHA) Meeting and
Exposition
November 4-8, 2006
Boston, MA
Visit: http://www.apha.org/meetings/
6th National Harm Reduction
Conference
November 8-12, 2006
Oakland, CA
Visit:
http://www.harmreduction.org/6national/
University of Texas Medical Branch
(UTMB) HIV Mini-Fellowship
November 13-15, 2006
Moody Gardens Hotel and Convention
Center
Galveston, TX
$50.00 Registration Fee
CME and CNE credits available
Contact: Victoria Korschgen
E-mail: vikorsch@utmb.edu
Phone: (409)747-2768
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LITERATURE REVIEWS

CDC Releases Revised Recommendations for HIV
Testing of Adults, Adolescents, and Pregnant
Women in Health-Care Settings
The Center for Disease Control and Prevention (CDC)
released Revised Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant Women in HealthCare Settings in the September 22 issue of Morbidity
and Mortality Week Report (MMWR). The new recommendations are intended to integrate voluntary HIV testing into routine medical care and to increase early HIV
diagnosis among the estimated one of four persons with
HIV infection in the U.S. who are not aware of their HIVpositive status.
The recommendations include voluntary HIV screening
for all persons between the ages of 13 and 64 years as
a standard practice of medical care. The recommendations also include an opt-out provision, allowing for
patients to refuse testing after they have received basic
information regarding HIV testing and treatment. To simplify HIV screening the CDC recommendations no longer
require pre-test counseling and written consent,
although the authors emphasize the importance of offering HIV-positive individuals post-test prevention counseling and access to care. Finally, the CDC contends that
pregnant women at high risk for HIV or in areas with high
HIV prevalence should be routinely tested for HIV in their
third trimester. The report also recommends that rapid
HIV tests be used for all women with unknown HIV status during labor. In early 2007, the CDC will issue further
guidelines for providers, including practical tools and
model approaches for implanting these recommendations.
CDC. Revised Recommendations for HIV Testing of
Adults, Adolescents, and Pregnant Women in HealthCare Settings. Morb Mortal Wkly
Rep.2006;55(RR14);1-17. Available at:
http://www.cdc.gov/mmwr/preview
/mmwrhtml/rr5514a1.htm
Prison Research Group Honored by CDC
The Prison HIV Seroincidence Group of the CDC
Division of HIV/AIDS Prevention (DHAP), received the
National Center for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP) Director's Recognition
Award for September. From September 2004 to April
2006, the Prison HIV Seroincidence Group conducted
the first large-scale investigation into HIV transmission in
a prison system in the U.S. (see IDCR May 2006). The
Group worked collaboratively with prisons and health
department personnel, interviewed 226 prisoners and 8
correctional officers in 31 Georgia prisons, and conducted focus groups with ex-inmates. In addition, they
obtained blood samples from the inmates, reviewed
inmate medical charts, conducted HIV testing, HIV phylogenetic testing, and HIV antiretroviral resistance testing. The Group collected data on illegal and stigmatizing
sex and drug behaviors in prison and the contexts and
dynamics that place inmates at risk for HIV infection, and
made recommendations for HIV prevention in corrections.
The Group's investigations identified and confirmed 88
cases of HIV transmission that occurred among inmates
during incarceration and identified factors associated
with HIV seroconversion. They also demonstrated the
existence of several clusters of ongoing HIV transmission as evidenced by seroconverters sharing common
HIV strains.

House Bill Would Require Federal Prisons to Provide
HIV Testing for Inmates
Early this month, California Representative Maxine
Waters (D) introduced a bill to the House that would
require HIV testing for all federal prison inmates upon
entry. The bill also includes an opt-out choice for inmates
who do not wish to be tested. The opt-out provision
acknowledges the complex issues of stigma and confidentiality often connected to HIV-positive status.
Additionally, to foster a continuum of care from prison to
the community, Waters' bill would require the Bureau of
Prisons to contact former HIV-infected inmates and
direct them to treatment and counseling in the community. Although the Bureau of Prisons' policies already
emphasis the importance of testing inmates, Waters contends that under her bill more inmates will be tested and
have greater access to care upon release. Skeptics
question the effectiveness of a bill that includes an optout provision since there is no way to tell just how many
inmates would refuse HIV testing.
Waters seeks to sway AIDS groups on prisoner testing.
Young J. The Hill. September 12, 2006. Available at
www.thehill.com.
HIV/AIDS, Sexually Transmitted Diseases (STDs) and
Incarceration Among Women
This large-scale retrospective study utilized secondary
data from federal and state corrections agencies to
examine the relationship between incarceration and HIV
and STD trends - focusing on black women living in
poverty in the rural south. Across the U.S., Hammett and
colleagues observed that an increasing proportion of
inmates are women, with disproportionate representation of black and Latino women. Of all regions, incarceration rates were highest in the South (790 per 100,000),
but unlike other areas, the South displayed similar rates
of incarceration between urban and rural residents. The
national prevalence of HIV and STDs was higher in
female inmates (for HIV 3%) than in incarcerated males
(for HIV 2%), and women releasees from the South suffer from one of the highest regional burdens of HIV with
15% of all Southern women released from a correctional
facility living with HIV.
These data indicate that the overlapping of the epidemics of HIV/STDs and incarceration is greatest in the
Southern U.S. Yet, despite the high prevalence of HIV
among women involved in the criminal justice system in
the South, it appears that only a small percentage (0.60.7%) of reported AIDS cases among women are diagnosed in prisons and jails. In response to this situation,
the authors highlight the importance of deploying programs to prevent, diagnose, and treat individuals both
within correctional facilities and rural community post
release.
Hammett T, Drachman-Jones A. Sexually Transmitted
Diseases. 2006;33(7):S17-22
Predictors of Post-Release Primary Care Utilization
Among HIV-positive Prison Inmates: A Pilot Study
Recognizing the importance of the post-release period to
the continuity of care in HIV positive inmates,
researchers in Texas set out to examine (1) the proportion of HIV positive inmates utilizing primary care after
release and (2) the variables associated with the utilization of primary care in the immediate post-release period. This pilot study of sixty inmates, both male and
Continued on page 11
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CONTINUING MEDICAL EDUCATION CREDIT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR. MEC is accredited by the
ACCME to provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should
only claim credit commensurate with the extent of their participation in the activity. Statements of credit will be mailed within 6 to 8 weeks following the program.
Objectives:
The learner will be able to describe major findings from the International AIDS Conference including results of clinical trials of HIV therapies
The learner will become familiar with data presented at the International AIDS Conference regarding HIV transmission prevention in correc
tional settings
The learner will be able to cite new recommendations made by the U.S. Centers for Disease Control and Prevention on HIV testing in the U.S.
A.
B.

1. According to the World Health Organization (WHO), all the following
regarding research on the provision of condoms in prisons are true
EXCEPT:
A. Available data suggest that providing condoms in prison
is feasible.
B. There is no direct evidence that providing condoms in
prisons reduces HIV transmission.
C. Security problems including use of condoms as weapons
and to smuggle contraband has been widely reported in
facilities providing inmates access to condoms.
D. None of the above.

C.
D.

Be offered to all persons in the U.S. aged 13 to 64 years.
Be performed without the need for a separate signed
consent or lengthy pre-test counseling.
Patients should be notified verbally that HIV testing is
being ordered and given an opportunity to opt out
of testing.
All the above.

4. According to data presented at the International AIDS Conference,
monotherapy of HIV infection with a ritonavir-boosted protease inhibitor:
A. Provided superior rates of virologic suppression as
HAART regimens containing a combination of
antiretrovirals.
B. Was associated with risk of protease inhibitor resistance.
C. Is highly successful and should become widely adopted as a
strategy for the treatment of HIV infection.
D. All the above.

2. In the AIDS Clinical Trials Group (ACTG) study A5142 of treatment
naïve patients, at 96 weeks:
A. A greater proportion of those assigned efavirenz plus two
nucleosides achieved an HIV viral load <50 copies/mL
than those assigned to lopinavir/ritonavir and two nucleo
sides.
B. Lopinavir/ritonavir plus two nucleosides led to greater.
C. A and B.
D. Neither A or B.

5. The recent Institute of Medicine report on ethics of research in prison
settings concluded that research investigations in correctional setting
should not be permitted (TRUE or FALSE)?
TRUE

3. The Centers for Disease Control and Prevention (CDC) now recommends that HIV testing?

or

FALSE
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LITERATURE REVIEWS

female, utilized qualitative and quantitative measures, obtained during interviews conducted
three months prior to release and seven to twenty one days after release. They found that only
60% of the participants not lost to follow-up
(n=30) utilized a primary care facility within the
twenty one day post-release period. Variables
positively associated with primary care usage
included: receiving anti-HIV medications at the
time of release, no alcohol usage since release,
living in the same location as prior to incarceration, and a rating of housing situation as "comfortable" or "very comfortable." A logistical
regression model comprised of these four variables correctly classified 80% of the cases in care
overall. The generalizability of the findings is limited by the small sample size, an issue that the
researchers plan to address in future studies.
Harzke A, Ross M, Scott D. AIDS Care.
2006;18(4):290-301
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Therapy
After
Suppression

Sustained

Virologic

Multiple studies have attempted to simplify multidrug antiretroviral therapies in order to reduce
long-term adverse effects, expense, and difficulty
of regimen adherence (See Main Article). The
AIDS Clinical Trials Group (ACTG), A5201 Study
Team, selected a ritonavir-boosted atazanavir
(Reyataz) approach to explore this possibility.
They proposed that the low-pill burden, oncedaily dosing, safety, and unique resistance profile
of atazanavir/ritonavir would make it a strong
candidate for simplified maintenance therapy. In
this multi-center pilot study 34 HIV-positive participants with persistent HIV RNA levels below 50
copies/mL while receiving their first protease
inhibitor antiretroviral regimen. All had their protease inhibitor switched to atazanavir/ritonavir at
study entry and the nucleosides discontinued at
six weeks. Over the 24 week study period, the
investigators observed an absence of virologic

failure - defined as two consecutive HIV-1 RNA
measurements of ?200 copies/mL - in 91% (31 of
34) of the subjects. Additionally, there were no
treatment discontinuations for adverse events following simplification, no significant changes in
CD4+ cell counts or plasma lipid levels, and no
detectable HIV-1 RNA in seminal plasma from the
eight participants providing semen. Resistance
testing in the three participants exhibiting virologic failure did not identify protease inhibitor resistance mutations, while 2 of the 3 participants
experiencing failure exhibited plasma atazanavir
concentrations low or below detection - suggesting potential suboptimal adherence to the study
regimen. These results suggest that ritonavir
boosted atazanavir may be efficacious in for simplified maintenance therapy in selected patients
with HIV infection and, at the least, is worthy of
further investigation.
Swindells A, DiRienzo G, Wilkin T, et al. the AIDS
Clinical Trials Group 5201 Study Team. JAMA.
2006;296:806-14.
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change the way you practice based
on what you learned in this activity?
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this activity?

II. Course Objectives
Were the following overall course objectives met? At the conclusion of this presentation, are you able to:

•

The learner will be able to describe major findings from the International AIDS

YES

NO

SOMEWHAT

YES

NO

SOMEWHAT

YES

NO

SOMEWHAT

Conference including results of clinical trials of HIV therapies

•

The learner will become familiar with data presented at the International AIDS Conference
regarding HIV transmission prevention in corretional settings

•

The learner will be able to cite new recommendations made by the U.S. Centers
for Disease Control and Prevention on HIV testing in the U.S.
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a. Suggested topics and/or speakers you would like for future activities.

b. Additional Comments

Poor

